Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia

Blood

Volumn 117, Issue 11, 2011, Pages 3209-3213

  Bertrand, Gerald ^a   Drame, Moustapha ^b   Martageix, Corinne ^a   Kaplan, Cecile ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HLA DR ANTIGEN; HUMAN PLATELET ANTIGEN 1A ANTIBODY; IMMUNOGLOBULIN; PREDNISONE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FETUS; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEROID THERAPY; THROMBOCYTE COUNT;

EID: 79953067695     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-302463     Document Type: Article

References (22)

1. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, Uzan S, Dreyfus M, Kaplan C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol. 1996;13(7):423-431. (Pubitemid 26425206)
2. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PLA1, Zwa) as determined by antenatal screening. Blood. 1998;92(7):2280-2287. (Pubitemid 28452968)
3. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1(8634):363-366. (Pubitemid 19103082)
4. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol. 2001;41(1):45-55. (Pubitemid 32201293)
5. Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood. 1988;72(1):340-343.
6. Bussel JB, Berkowitz RL, McFarland JG, Lynch L, Chitbara N. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med. 1988; 319(21):1374-1378.
7. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996;174(5):1414-1423. (Pubitemid 26165254)
8. Kaplan C, Murphy MF, Kroll H, Waters AH. Fetomaternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids - more questions than answers. Br J Haematol. 1998;100(1): 62-65. (Pubitemid 28051841)
9. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107(1):91-96.
10. Bertrand G, Jallu V, Gouet M, et al. Quantification of human platelet antigen-1a antibodies with the monoclonal antibody immobilization of platelet antigens procedure. Transfusion. 2005;45(8): 1319-1323. (Pubitemid 41647797)
11. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA-1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica. 2008;93(6):870-877. (Pubitemid 351821723)
12. Bertrand G, Martageix C, Jallu V, Vitry F, Kaplan C. Predictive value of sequential maternal anti- HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost. 2006;4(3):628-637.
13. Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Current trends in neonatal alloimmune thrombocytopenia diagnosis and therapy. In: Kaplan- Gouet C, Schlegel N, Salmon C, MacGregor J, eds. Platelet Immunology: Fundamental and Clinical Aspects. Vol 206. Paris, France: John Libbey-Eurotex/ ed.Inserm; 1991:267-278.
14. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839. (Pubitemid 47267418)
15. Proulx C, Filion M, Goldman M, et al. Analysis of immunoglobulin class, IgG subclass and titre of HPA-1a antibodies in alloimmunized mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol. 1994; 87(4):813-817. (Pubitemid 24264655)
16. Bessos H, Turner M, Urbaniak SJ. Is there a relationship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia? Immunohematology. 2005;21(3):102-109.
17. Ahlen MT, Killie MK, Husebekk A, et al. The development of severe anti-HPA 1a-related neonatal alloimmune thrombocytopenia is influenced by the maternal ABO type. Blood. 2007;110(11):Abstract 2093
18. Killie MK, Salma W, Berteisen E, Skogen B, Husebekk A. Quantitative MAIPA: comparison of different MAIPA protocols. Transfus Apher Sci. 2010;43(2):149-154.
19. Berkowitz RL, Lesser ML, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol. 2007;110(2):249-255. (Pubitemid 47356647)
20. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood. 2006;107(7):2976-2983.
21. Chen P, Li C, Lang S, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010;116(18):3384-3386.
22. Skogen B, Husebekk A, Killie MK, Kjeldsen- Kragh J. Neonatal alloimmune thrombocytopenia is not what it was: a lesson learned from a large prospective screening and intervention program. Scand J Immunol. 2009;70(6):531-534.